Korea Pharma Signs Exclusive Domestic Sales and Distribution Agreement for Two Schizophrenia Treatments

Korea Pharma announced on the 4th that it has signed an exclusive domestic sales and distribution agreement with Johnson & Johnson's pharmaceutical division in Korea, Korea Janssen, for the schizophrenia treatments Invega Extended-Release Tablets (active ingredient paliperidone) and Risperdal Tablets (active ingredient risperidone).

From the left, Christian Rodses, President of Janssen Korea, and Eunhee Park, CEO of Korea Pharma. Provided by Korea Pharma

Under this agreement, Korea Pharma will be responsible for the distribution and sales of Invega Extended-Release Tablets and Risperdal Tablets supplied to all hospitals and clinics nationwide starting this month. The company plans to further strengthen its position in the central nervous system (CNS) market and introduce additional CNS disorder treatments. The company explained that it expects to play an even more important role in the domestic schizophrenia treatment market in the future.

Park Eun-hee, CEO of Korea Pharma, stated, "We will provide medications that offer real benefits to schizophrenia patients and enhance our competitiveness in CNS disorder treatments," adding, "Through continuous innovation and a patient-centered approach, we will lead the CNS disorder treatment market."

Korea Pharma currently sells over 30 CNS disorder treatments, including those for schizophrenia, bipolar disorder, depression, anxiety, insomnia, dementia, epilepsy, and Parkinson's disease. These medications are prescribed across virtually all areas of mental illness, and with changing perceptions of psychiatry and social issues, the demand for CNS disorder treatments is increasing.

This content was produced with the assistance of AI translation services.